Indicators of the functions of the hepatobiliary system in patients with chronic opisthrochisis with genetic predisposition to the development of ischemic heart disease

To assess the influence of genetic features that provide a predisposition to the development of coronary heart disease on the reactivity of the hepatobiliary system in opisthorchiasis invasion, a study of biochemical parameters was conducted in subgroups of patients with chronic opisthorchiasis with and without mutations in the corresponding loci. It was found that the presence of a mutation in the rs133304 locus of the CDKN 2A/2B gene increases deviations in GGT activity from the level of healthy individuals caused by opisthorchiasis invasion, apparently aggravating bile secretion disorders, and slows down the normalization of the integral indicator of the state of hepatocytes – bilirubin – after treatment, while contributing to a decrease in cholesterol concentration and an increase in glucose concentration during treatment. The presence of a rare allele in the rs17602729 locus of the AMPD1 gene, on the contrary, has a protective effect on the process of bile secretion in CO (judging by the activity of GGT and ALP), and also smooths out changes in the parameters during therapy. The presence of a mutant allele in the rs133304 locus of the HIF1A gene prevents an increase in the concentration of bilirubin and glucose, accelerates the normalization of GGT activity after therapy, which can be considered a positive effect in CO, but does not affect the increase in ALP activity in the first days after treatment, reflecting the persistence of difficulties in bile secretion. Mutation in the rs3025058 locus of the MMP3 gene has some positive effect on the dynamics of changes in aminotransferases and bilirubin and cholesterol levels during treatment, but contributes to an increase in glucose levels after therapy.

1. Bakshtanovskaya I.V., Stepanova K.B., Ozerova A.N., Stepanova T.F., Zmatrakova E.A. Indicators of hepatobiliary system functions in patients with chronic opisthorchiasis with a genetic predisposition to lipid metabolism disorders // Med parasitol (Mosk). 2023; 4: 22-29. (in Russian)] DOI: 10.33092/0025-8326mp2023.4.22-29.

2. Stepanova T.F. Opisthorchiasis: new views on the invasive disease, the basics of clinical rehabilitation, the methodology of largescale recreational work. Tyumen.2002: 196 (in Russian)].

3. Bakshtanovskaya I.V., Stepanova K.B., Kal’gina G.A., Stepanova T.F. Relationships between biochemical and immunological parameters in patients with chronic opisthorchiasis // Med parasitol (Mosk). 2018; 2: 13-19. (in Russian)].

4. Grigorieva I.N. Opisthorchiasis: traditions and innovations. Experimental and clinical gastroenterology. 2012: 4: 54-59. (in Russian)].

5. Han D., Zhang H., Liu S., Zhuang L., Zhao Z., Ding H., Xin Y. Association between the LRP5 rs556442 gene polymorphism and the risks of NA-FLD and CHD in a Chinese Han population // BMC gastroenterology, 2022; 22(1): 305. DOI:10.1186/s12876-022-02385-9.

6. Miura T., Kouzu H., Tanno M., Tatekoshi Y., Kuno A. Role of AMP deaminase in diabetic cardiomyopathy // Mol Cell Biochem. 2024; 479(12): 3195-3211. DOI: 10.1007/s11010-024-04951-z.

7. Feng A.F., Liu Z.H., Zhou S.L., Zhao S.Y., Zhu Y.X., Wang H.X. Effects of AMPD1 gene C34T polymorphism on cardiac index, blood pressure and prognosis in patients with cardiovascular diseases: a meta-analysis // BMC Cardiovasc Disord. 2017; 17 (1): 174. DOI: 10.1186/s12872-017-0608-0.

8. Tandelilin A.A., Hirase T., Hudoyo A.W., et al. AMPD1 regulates mTORC1-p70 S6 kinase axis in the control of insulin sensitivity in skeletal muscle // BMC Endocr Disord. 2015; 15: 11. DOI: 10.1186/s12902-015-0010-9.

9. Tibaut M., Naji F., Petrovič D. Association of myocardial infarction with CDKN2B antisense RNA 1 (CDKN2B-AS1) rs1333049 polymorphism in slovenian subjects with type 2 diabetes mellitus // Genes (Basel). 2022; 13(3): 526. DOI: 10.3390/genes13030526.

10. Zhao J., Wu X., Nie S., et al. Association of CDKN2B-AS1 rs1333049 with brain diseases: a casecontrol study and a metaanalysis // Clin Psychopharmacol Neurosci. 2017; 15 (1): 53-58. DOI: 10.9758/cpn.2017.15.1.53.

11. Shen X., Li Y., He F., Kong J. LncRNA CD-KN2B-AS1 promotes cell viability, migration, and invasion of hepatocellular carcinoma via sponging miR-424-5p // Cancer Manag Res. 2020; 12: 6807-6819. DOI: 10.2147/CMAR.S240000.

12. Xie F., Dong J., Zhu Y., Wang K., Liu X., Chen D., Meng Q. HIF1a Inhibitor Rescues Acute-on-Chronic Liver Failure // Ann Hepatol. 2019; 18(5): 757-764. DOI: 10.1016/j.aohep.2019.03.007.

13. Mücke M.M., El Bali N., Schwarzkopf K.M., Uschner F.E., Kraus N., Eberle L., Mücke V.T., Bein J., Beyer S., Wild P.J., Schierwagen R., Klein S., Zeuzem S., Welsch C., Trebicka J., Brieger A. The role of hypoxia-inducible factor 1 alpha in acuteonchronic liver failure // Int J Mol Sci. 2024; 25(3): 1542. DOI: 10.3390/ijms25031542

14. Li H.N., He T., Zha Y.J., Du F., Liu J., Lin H.R., Yang W.Z. HIF-1α rs11549465 C>T polymorphism contributes to increased cancer susceptibility: Evidence from 49 studies // J Cancer. 2019; 10 (24): 5955-5963. DOI: 10.7150/jca.35716.

15. Pleskovič A., Letonja M.Š., Vujkovac A.C., Starčević J.N., Caprnda M., Curilla E., Mozos I., Kruzliak P., Prosecky R., Petrovič D. Matrix metalloproteinase-3 gene polymorphism (rs3025058) affects markers atherosclerosis in type 2 diabetes mellitus // Vasa. 2017; 46(5): 363-369. DOI:10.1024/0301-1526/a000637.

16. Shin H.P., Lee J.I., Jung J.H., Yim S.V., Kim H.J., Cha J.M., Park J.B., Joo K.R., Hwang J.S., Jang B.K. Matrix metalloproteinase (MMP)-3 polymorphism in patients with HBV related chronic liver disease // Dig Dis Sci. 2008; 53(3): 823-829. DOI :10.1007/s10620-007-9937-7.

17. Wang W., Peng W.H., Lu L., Zhang R.Y., Zhang Q., Wang L.J., Chen Q.J., Shen W.F. Polymorphism on chromosome 9p21.3 contributes to earlyonset and severity of coronary artery disease in nondiabetic and type 2 diabetic patients // Chin Med J (Engl). 2011; 124(1): 66-71. DOI: 10.3901/jme.2011.08.066.

18. Luo M., Li T., Sang H. The role of hypoxia-inducible factor 1α in hepatic lipid metabolism // J Mol Med (Berl). 2023; 101(5): 487-500. DOI: 10.1007/s00109-023-02308-5.

19. Lu Y., Sui J., Liu Y., Li R., Ma L., Zhang X., Qin X., Li S. Association between hypoxia-inducible factor-1α gene polymorphisms and risk of chronic hepatitis B and hepatitis B virusrelated liver cirrhosis in a Chinese population: a retrospective casecontrol study // Gene. 2015; 564(1): 96-100. DOI: 10.1016/j.gene.2015.03.053.

20. Norcia L.F., Watanabe E.M., Hamamoto Filho P.T., Hasimoto C.N., Pelafsky L., de Oliveira W.K., Sassaki L.Y. Polycystic liver disease: pathophysiology, diagnosis and treatment // Hepatic medicine: evidence and research, 2022; 14: 135-161. DOI: 10.2147/HMER.S377530.